Clinical Trial Update: Macitentan in the Treatment of Organ Rejection After Lung Transplantation [Phase 4]

View source ↗

Summary

Phase 4 trial investigating macitentan for organ rejection after lung transplantation has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Transplant Rejection

Drugs mentioned

• Macitentan (macitentan)

Snippet

Sponsor: University of California, Los Angeles | Conditions: Lung Transplant Rejection | Phase 4 | Status: WITHDRAWN